Literature DB >> 2791444

The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose.

R A Boyd1, S K Chin, O Don-Pedro, D Verotta, L B Sheiner, R L Williams, K M Giacomini.   

Abstract

A potential complicating factor in the characterization of the pharmacokinetics and pharmacodynamics of diltiazem after an oral dose in the presence of two metabolites, N-demethyldiltiazem and desacetyldiltiazem, in plasma. Both N-demethyldiltiazem and desacetylditiazem have been shown to have pharmacologic activity in animal tissues. It is therefore possible that these metabolites contribute to the pharmacologic effect of diltiazem, but this possibility has not been explored. The purpose of this study was to investigate the pharmacokinetics and pharmacodynamics of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem. Particular attention was paid to the effect of diltiazem on atrioventricular conduction. Six healthy men received a 120 mg oral dose of diltiazem. Concentrations of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem in plasma and urine were measured by a sensitive HPLC method. Measures of pharmacologic response (heart rate, blood pressure, and PR interval) were obtained at each blood sampling time. Mean (+/- SD) peak plasma concentrations of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem were 174.3 +/- 72.7, 42.6 +/- 10.0, and 14.9 +/- 3.3 ng/ml, respectively. The apparent half-lives of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem were 6.5 +/- 1.4 hours, 9.4 +/- 2.2 hours, and 18 +/- 6.2 hours, respectively. Both N-demethyldiltiazem and diltiazem were eliminated by net secretion, whereas the renal clearance of desacetyldiltiazem did not exceed clearance by filtration. Both N-demethyldiltiazem and desacetyldiltiazem are bound to plasma proteins, with unbound fractions of 0.323 +/- 0.035 and 0.230 +/- 0.021. These values are similar to the unbound fraction of diltiazem (0.254 +/- 0.027). No significant effect of diltiazem on blood pressure or heart rate was noted. However, a prolongation of the PR interval was observed in all six subjects. Furthermore, an apparent clockwise hysteresis in the concentration-effect relationship was found in four of the six subjects. These findings suggest that some form of acute tolerance to the electrophysiologic effect of diltiazem develops, but the results of pharmacodynamic modeling suggest that this is not caused by the antagonistic effects the metabolites.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2791444     DOI: 10.1038/clpt.1989.159

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers.

Authors:  E Bellissant; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

2.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

3.  Prolongation of the PQ interval as a measure of therapeutic inequivalence between two formulations of diltiazem.

Authors:  O E Della Paschoa; V Luckow; D Trenk; E Jähnchen; S R Santos
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 4.  Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions.

Authors:  R Mick; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Prediction of diltiazem plasma concentration curves from limited measurements using compliance data.

Authors:  A Rubio; C Cox; M Weintraub
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

6.  Pharmacokinetics and metabolism of diltiazem in rabbits after a single intravenous or single oral administration.

Authors:  P K Yeung; S J Mosher; P T Pollak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

Review 7.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

8.  Pharmacokinetics of diltiazem and a new analogue, LR-A/113, in the conscious rat.

Authors:  R Bernasconi; S Caliari; R Latini; D Leopaldi; S Porzio; A Salimbeni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Oct-Dec       Impact factor: 2.441

9.  A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers.

Authors:  P Francheteau; J L Steimer; H Merdjan; M Guerret; C Dubray
Journal:  J Pharmacokinet Biopharm       Date:  1993-10

10.  Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure.

Authors:  Y H Lee; M H Lee; C K Shim
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.